Education
About Us
Working with TipRanks
Follow Us
Minerva Neurosciences (NERV)
NASDAQ:NERV
NERV Stock Chart & Stats
$4.00
-$0.09(-3.83%)
At close: 4:00 PM EST
$4.00
-$0.09(-3.83%)
Day’s Range― - ―
52-Week Range$1.15 - $12.46
Previous CloseN/A
Volume1.19K
Average Volume (3M)465.60K
Market Cap
$25.67M
Enterprise Value$57.67M
Total Cash (Recent Filing)$12.29T
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)2.5
Beta1.60
Next Earnings
Mar 10, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding6,993,406
10 Day Avg. Volume1,362,901
30 Day Avg. Volume465,600
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.86
Enterprise Value/Market Cap2.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-42.37K
Enterprise Value/Ebitda-5.62
Forecast
1Y Price Target
$4.00Price Target Upside0.00%
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Safety ProfileThe study demonstrated an acceptable safety profile of co-administration of the two medications, and no relevant PK interactions were observed between the two drugs.
Strategic PartnershipBoehringer Ingelheim owns 18% of the company after taking a stake in Minerva, so it is suspected they will support the further development of roluperidone.
Bears Say
Financial PositionThe company reported cash at $21.5M compared with the cash position at $41M previously; the company should have approximately one-year cash runway.
Regulatory ChallengesThe company's efforts to avoid needing to do another Phase 3 study appears to be counterproductive since the Agency has made it clear on the need for at least one additional study to support the safety and effectiveness of roluperidone.
Minerva Neurosciences News
NERV FAQ
What was Minerva Neurosciences’s price range in the past 12 months?
Minerva Neurosciences lowest stock price was $1.15 and its highest was $12.46 in the past 12 months.
What is Minerva Neurosciences’s market cap?
Minerva Neurosciences’s market cap is $25.67M.
When is Minerva Neurosciences’s upcoming earnings report date?
Minerva Neurosciences’s upcoming earnings report date is Mar 10, 2026 which is in 116 days.
How were Minerva Neurosciences’s earnings last quarter?
Minerva Neurosciences released its earnings results on Nov 05, 2025. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.36.
Is Minerva Neurosciences overvalued?
According to Wall Street analysts Minerva Neurosciences’s price is currently same.
Does Minerva Neurosciences pay dividends?
Minerva Neurosciences does not currently pay dividends.
What is Minerva Neurosciences’s EPS estimate?
Minerva Neurosciences’s EPS estimate is -0.11.
How many shares outstanding does Minerva Neurosciences have?
Minerva Neurosciences has 6,993,406 shares outstanding.
What happened to Minerva Neurosciences’s price movement after its last earnings report?
Minerva Neurosciences reported an EPS of -$0.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.087%.
Which hedge fund is a major shareholder of Minerva Neurosciences?
Currently, no hedge funds are holding shares in NERV
Company Description
Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company primarily focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is engaged in creating innovative therapies for patients suffering from neuropsychiatric disorders, including schizophrenia, depression, and Parkinson's disease, with its core product candidates being roluperidone and MIN-301.
NERV Stock 12 Month Forecast
Average Price Target
$4.00
▲(0.00% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Pulmatrix
―
Chemomab Therapeutics
―
Abpro Holdings
―
Aspire Biopharma Holdings
―
Ownership Overview
6.80%
Insiders
21.48% Mutual Funds
0.56% Other Institutional Investors
67.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---